About: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Creator	Rollin, Pierre Bergeron, Eric Ksiazek, Thomas Benjannet, Suzanne Nichol, Stuart Vincent, Martin Erickson, Bobbie Seidah, Nabil Erickson -Berickson1@cdc, Bobbie Gov;, Gov;, Pierre Gov;, Rollin -Prollin@cdc Ksiazek -Tksiazek@cdc, Thomas
Source	Medline; PMC
abstract	BACKGROUND: Severe acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available. RESULTS: We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage. In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and spread of SARS CoV at clinically admissible concentrations. CONCLUSION: Chloroquine is effective in preventing the spread of SARS CoV in cell culture. Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence assay described herein represents a simple and rapid method for screening SARS-CoV antiviral compounds.
has issue date	2005-08-22(xsd:dateTime)
bibo:doi	10.1186/1743-422x-2-69
bibo:pmid	16115318
has license	cc-by
sha1sum (hex)	a4b16ad01125dda3a5dd4ae97fe8cb53c9538075
schema:url	https://doi.org/10.1186/1743-422x-2-69
resource representing a document's title	Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
has PubMed Central identifier	PMC1232869
has PubMed identifier	16115318
schema:publication	Virol J
resource representing a document's body	covid:a4b16ad01125dda3a5dd4ae97fe8cb53c9538075#body_text
is schema:about of	named entity 'prophylactic' named entity 'caused' covid:arg/a4b16ad01125dda3a5dd4ae97fe8cb53c9538075 named entity 'SARS-CoV' named entity 'Severe acute respiratory syndrome' named entity 'Chloroquine' named entity 'monoclonal antibody' named entity 'antibody' named entity 'Golgi' named entity 'antiviral effect' named entity 'SARS-CoV' named entity 'endosomal' named entity 'antibody' named entity 'similar manner' named entity 'infection' named entity 'chloroquine' named entity 'chloroquine' named entity 'cell culture' named entity 'ACE2' named entity 'infection' named entity 'FITC' named entity 'glycoprotein' named entity 'prophylactic' named entity 'NH 4' named entity 'endosomes' named entity 'acidic pH' named entity 'NH 4' named entity 'infection' named entity 'infection' named entity 'Golgi' named entity 'immunoreactive' named entity 'chloroquine' named entity 'NH 4' named entity 'immunoprecipitated' named entity 'Invitrogen' named entity 'NH 4' named entity 'infection' named entity 'glycosylation' named entity 'chloroquine' named entity 'chloroquine' named entity 'multiplicity of infection' named entity 'SARS-CoV' named entity 'biosynthesis' named entity 'chloroquine' named entity 'IgG antibody' named entity 'Golgi' named entity 'SARS-CoV' named entity 'ACE2' named entity 'chloroquine' named entity 'electrophoretic mobility' named entity 'ACE2' named entity 'quantitative RT-PCR' named entity 'SARS-CoV' named entity 'DNA vaccination' named entity 'infection' named entity 'animal models' named entity 'SARS-CoV' named entity 'N-glycosylated' named entity 'spike protein' named entity 'infection' named entity 'adsorption' named entity 'chloroquine' named entity 'mammalian cells' named entity 'SARS-CoV' named entity 'SARS-CoV' named entity 'pathogen' named entity 'cellular functions' named entity 'spike protein' named entity 'antiviral effect'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software